Evidence Of Accused Product Provides Meaningful Context For Claim Construction Analysis
Client Alert | 1 min read | 03.30.06
In Wilson Sporting Goods Co. v. Hillerich & Bradsby Co. (No. 05-1103, March 23, 2006), the Federal Circuit revisits its rule that “claims may not be construed with reference to the accused device.” In the district court, defendant's baseball and softball bats were accused of infringing a patent directed to a bat having a special “insert” within its body. Following the district court's claim construction of the terms “insert” and “gap,” the parties stipulated that the accused products do not infringe. The patentee appealed the claim construction ruling, but the record on appeal did not include a description of the accused products.
According to the Federal Circuit, it reviews claim construction only as necessary to reach final judgment and that, without evidence of the accused products, this appeal “assumes many attributes of a proceeding seeking an advisory opinion on the scope of the patent.” While claim construction should not be biased to include or exclude features of an accused product, the Court clarifies that awareness of the accused product supplies the Court with the parameters and scope of the infringement analysis. The Federal Circuit concludes that without that additional context it cannot fully review the judgment of non-infringement, including its claim construction component. The Federal Circuit ultimately construed the terms “insert” and “gap,” but reiterated that it did so without full context of this infringement action and that on remand the district court “may reconsider its construction in light of this opinion.”
Insights
Client Alert | 5 min read | 12.12.25
Eleventh Circuit Hears Argument on False Claims Act Qui Tam Constitutionality
On the morning of December 12, 2025, the Eleventh Circuit heard argument in United States ex rel. Zafirov v. Florida Medical Associates, LLC, et al., No. 24-13581 (11th Cir. 2025). This case concerns the constitutionality of the False Claims Act (FCA) qui tam provisions and a groundbreaking September 2024 opinion in which the United States District Court for the Middle District of Florida held that the FCA’s qui tam provisions were unconstitutional under Article II. See United States ex rel. Zafirov v. Fla. Med. Assocs., LLC, 751 F. Supp. 3d 1293 (M.D. Fla. 2024). That decision, penned by District Judge Kathryn Kimball Mizelle, was the first success story for a legal theory that has been gaining steam ever since Justices Thomas, Barrett, and Kavanaugh indicated they would be willing to consider arguments about the constitutionality of the qui tam provisions in U.S. ex rel. Polansky v. Exec. Health Res., 599 U.S. 419 (2023). In her opinion, Judge Mizelle held (1) qui tam relators are officers of the U.S. who must be appointed under the Appointments Clause; and (2) historical practice treating qui tam and similar relators as less than “officers” for constitutional purposes was not enough to save the qui tam provisions from the fundamental Article II infirmity the court identified. That ruling was appealed and, after full briefing, including by the government and a bevy of amici, the litigants stepped up to the plate this morning for oral argument.
Client Alert | 8 min read | 12.11.25
Director Squires Revamps the Workings of the U.S. Patent Office
Client Alert | 8 min read | 12.10.25
Creativity You Can Use: CJEU Clarifies Copyright for Applied Art
Client Alert | 4 min read | 12.10.25
Federal Court Strikes Down Interior Order Suspending Wind Energy Development
